Unione Europea - italiano - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - infezioni da hiv - antivirali per uso sistemico - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Unione Europea - italiano - EMA (European Medicines Agency)

pfizer europe ma eeig - sirolimus - graft rejection; kidney transplantation - immunosoppressori - rapamune è indicato per la profilassi del rigetto d'organo in pazienti adulti a basso-moderato rischio immunologico che ricevono un trapianto renale. si raccomanda di utilizzare rapamune inizialmente in combinazione con ciclosporina in microemulsione e corticosteroidi per 2 per 3 mesi. rapamune può essere continuato come terapia di mantenimento con corticosteroidi solo se la ciclosporina in microemulsione può essere progressivamente eliminata. rapamune è indicato per il trattamento di pazienti con sporadici linfangioleiomiomatosi con moderata malattia polmonare o di declino della funzione polmonare.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

teva italia s.r.l. - darunavir - darunavir

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - clotrimazolum - creme - clotrimazolum 10 mg, sorbitani stearas, polysorbatum 60, cetylis palmitas, alcohol cetylicus et stearylicus 100 mg, octyldodecanolum, aqua purificata, alcohol benzylicus 20 mg, ad unguentum pro 1 g. - antifungini - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - clotrimazolum - vaginaltabletten - clotrimazolum 100 mg, calcii lactas pentahydricus, cellulosum microcristallinum, crospovidonum, hypromellosum, acidum lacticum, lactosum monohydricum, maydis amylum, magnesii stearas, silica colloidalis anhydrica, pro compresso. - alcune infezioni vaginali con funghi - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - clotrimazolum - vaginaltabletten - clotrimazolum 200 mg, calcii lactas pentahydricus, cellulosum microcristallinum, crospovidonum, hypromellosum, acidum lacticum, lactosum monohydricum, maydis amylum, magnesii stearas, silica colloidalis anhydrica, pro compresso. - alcune infezioni vaginali con funghi - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - clotrimazolum - vaginaltabletten - clotrimazolum 500 mg, calcii lactas pentahydricus, cellulosum microcristallinum, crospovidonum, hypromellosum, acidum lacticum, lactosum monohydricum, maydis amylum, magnesii stearas, silica colloidalis anhydrica, pro compresso. - alcune infezioni vaginali con funghi - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - clotrimazolum - spray zur anwendung auf der haut, lösung - clotrimazolum 10 mg, macrogolum 400, alcohol isopropylicus, propylenglycolum 546 mg, ad solutionem pro 1 ml. - antifungini - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bayer (schweiz) ag - clotrimazolum - vaginalcrème - clotrimazolum 20 mg, alcohol benzylicus 20 mg, alcohol cetylicus et stearylicus 100 mg, cetylis palmitas, octyldodecanolum, polysorbatum 60, aqua purificata, sorbitani stearas, ad unguentum pro 1 g. - alcune infezioni vaginali con funghi - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

bailleul (suisse) sa - clotrimazolum, hexamidini diisetionas, prednisoloni acetas - crema - clotrimazolum 10 mg, hexamidini diisetionas 2.5 mg, prednisoloni acetas 5 mg, paraffinum perliquidum, glyceroli stearas, macrogoli 6 stearas, macrogoli 32 stearas, macrogolglyceridorum laurates, dimeticonum 350, octyldodecanolum, dinatrii edetas, aqua purificata, acidum citricum monohydricum, natrii hydroxidum, e 320 0.5 mg, ad unguentum pro 1 g. - infezioni della pelle, malattie infiammatorie/infezioni fungine della pelle - synthetika